Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1990 1
1993 1
1994 1
1997 1
1998 1
1999 1
2000 4
2001 1
2002 2
2003 3
2004 1
2006 4
2007 2
2008 1
2010 1
2011 4
2012 4
2013 4
2014 11
2015 4
2016 3
2017 8
2018 8
2019 3
2020 5
2021 5
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Primary Peritoneal Endometrioid Adenocarcinoma"
Page 1
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Moore K, et al. N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21. N Engl J Med. 2018. PMID: 30345884 Clinical Trial.
METHODS: We conducted an international, randomized, double-blind, phase 3 trial to evaluate the efficacy of olaparib as maintenance therapy in patients with newly diagnosed advanced (International Federation of Gynecology and Obstetrics stage III or IV) high-grade serous or en …
METHODS: We conducted an international, randomized, double-blind, phase 3 trial to evaluate the efficacy of olaparib as maintenance therapy …
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Coleman RL, et al. Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12. Lancet. 2017. PMID: 28916367 Free PMC article. Clinical Trial.
BACKGROUND: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. ...Eligible patients were aged 18 years or older, had a platinum-sens …
BACKGROUND: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a B …
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL. Ledermann JA, et al. Lancet Oncol. 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9. Lancet Oncol. 2020. PMID: 32359490 Free PMC article.
METHODS: In this ongoing (enrolment complete) randomised, placebo-controlled, phase 3 trial, patients aged 18 years or older who had platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma and an E …
METHODS: In this ongoing (enrolment complete) randomised, placebo-controlled, phase 3 trial, patients aged 18 years or older who had platinu …
The Prediction of Recurrence in Low-Risk Endometrial Cancer: Is It Time for a Paradigm Shift in Adjuvant Therapy?
Laban M, El-Swaify ST, Ali SH, Refaat MA, Sabbour M, Farrag N, Hassanin AS. Laban M, et al. Reprod Sci. 2022 Apr;29(4):1068-1085. doi: 10.1007/s43032-021-00565-8. Epub 2021 Apr 15. Reprod Sci. 2022. PMID: 33856667 Review.
Five to 10% of patients with stage IA, grade 1 or 2, endometrioid adenocarcinoma subsequently develop locoregional or distant recurrence. ...A systematic search of the literature on PubMed and Medline was conducted using the following search terms: endometrial cance …
Five to 10% of patients with stage IA, grade 1 or 2, endometrioid adenocarcinoma subsequently develop locoregional or distant …
Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
Kayahashi K, Mizumoto Y, Matsuoka A, Obata T, Iwadare J, Nakamura M, Daikoku T, Fujiwara H. Kayahashi K, et al. BMC Cancer. 2021 Jan 7;21(1):32. doi: 10.1186/s12885-020-07737-w. BMC Cancer. 2021. PMID: 33413178 Free PMC article.

P-cadherin was intensely and broadly expressed in mucinous, endometrioid, and serous subtypes (P < 0.01). Disseminated tumors demonstrated similar P-cadherin expression to primary tumors whereas metastatic lymph nodes demonstrated significantly decreased expressi

…

P-cadherin was intensely and broadly expressed in mucinous, endometrioid, and serous subtypes (P < 0.01). Disseminated tumors demo

…
Primary tumor types and origins in positive abdominopelvic washing cytology, a single institution experience.
Hou Y, Bruehl FK, McHugh KE, Reynolds JP. Hou Y, et al. J Am Soc Cytopathol. 2020 Mar-Apr;9(2):89-94. doi: 10.1016/j.jasc.2019.10.001. Epub 2019 Oct 14. J Am Soc Cytopathol. 2020. PMID: 31734259
The common ovarian tumors identified in pelvic washing in descending order were: high-grade serous carcinoma, serous borderline tumor, clear cell carcinoma, low-grade serous carcinoma, and endometrioid carcinoma. ...The majority of the positive …
The common ovarian tumors identified in pelvic washing in descending order were: high-grade serous carcinoma, serous borderline tumor …
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW. Holloway RW, et al. Int J Gynecol Cancer. 2023 Sep 4;33(9):1458-1463. doi: 10.1136/ijgc-2023-004812. Int J Gynecol Cancer. 2023. PMID: 37666539 Clinical Trial.
MAJOR INCLUSION/EXCLUSION CRITERIA: Eligible patients must have recurrent, platinum-resistant/refractory, non-resectable high-grade serous, endometrioid, or clear-cell ovarian, fallopian tube, or primary peritoneal cancer. Patients must have had 3 lines of pr …
MAJOR INCLUSION/EXCLUSION CRITERIA: Eligible patients must have recurrent, platinum-resistant/refractory, non-resectable high-grade serous, …
Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma.
Yoneoka Y, Yoshida H, Ishikawa M, Shimizu H, Uehara T, Murakami T, Kato T. Yoneoka Y, et al. J Gynecol Oncol. 2019 Jan;30(1):e7. doi: 10.3802/jgo.2019.30.e7. Epub 2018 Sep 17. J Gynecol Oncol. 2019. PMID: 30479091 Free PMC article.
OBJECTIVE: Gynecologists occasionally encounter synchronous endometrial and ovarian endometrioid carcinoma (SEO-EC) patients who show favorable prognosis than locally advanced or metastatic disease patients. ...RESULTS: From the multivariate analysis, cervical strom …
OBJECTIVE: Gynecologists occasionally encounter synchronous endometrial and ovarian endometrioid carcinoma (SEO-EC) patients w …
The peritoneal cancer index as a predictor of complete cytoreduction at primary and interval cytoreductive surgery in advanced ovarian cancer.
Fagan PJ, Gomes N, Heath OM, Chandrasekaran D, Yao SE, Satchwell L, George A, Banerjee S, Sohaib A, Barton DP, Nobbenhuis M, Ind T, Butler J. Fagan PJ, et al. Int J Gynecol Cancer. 2023 Nov 6;33(11):1757-1763. doi: 10.1136/ijgc-2022-004093. Int J Gynecol Cancer. 2023. PMID: 37890875
OBJECTIVE: The peritoneal cancer index quantitatively assesses cancer distribution and tumor burden in the peritoneal cavity. ...The most common stage was III (13% stage II, 53% stage III, 34% stage IV) and the most common histologic sub-type was high-grade serous ( …
OBJECTIVE: The peritoneal cancer index quantitatively assesses cancer distribution and tumor burden in the peritoneal cavity. …
Prognostic significance of peritoneal cytology in low-intermediate risk endometrial cancer.
Scott SA, van der Zanden C, Cai E, McGahan CE, Kwon JS. Scott SA, et al. Gynecol Oncol. 2017 May;145(2):262-268. doi: 10.1016/j.ygyno.2017.03.011. Epub 2017 Mar 28. Gynecol Oncol. 2017. PMID: 28359690
OBJECTIVES: There is uncertainty surrounding the prognostic value and clinical utility of peritoneal cytology in endometrial cancer. Our primary objective was to determine if positive cytology is associated with disease-free and overall survival in women treated sur …
OBJECTIVES: There is uncertainty surrounding the prognostic value and clinical utility of peritoneal cytology in endometrial cancer. …
81 results